Fritextsökning
Innehållstyper
-
Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”
The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well ...
-
“The US matters most – even in times of turbulence”
Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and fast...
-
New ZEISS Crossbeam 750 FIB-SEM for high-accuracy sample preparation workflows
Advances in simultaneous SEM imaging while FIB milling provide unmatched feedback for precision endpointing.
-
New antibody aims to slow kidney damage – “It’s kind of cool”
For 25 years, Marie Jeansson has studied the kidney and its blood vessels. She is now working on developing a drug intended to slow down chronic kidney disease.
-
Gene therapy restored hearing in children with congenital deafness
Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...
-
Clinical evaluation of class I medical devices
The Swedish Medtech Regulatory Summit is just around the corner — taking place on March 12th at Hilton Slussen in Stockholm. We’re proud to share that our Senio...
-
“Access to capital increases when there’s an exit”
It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...
-
Gene therapies on clinical hold after tumour found in five‑year‑old
The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio,...
-
A food-based strategy to stop gut infections early
Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier b...
-
ZEISS Connected Quality: One metrology hub
The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.
-
End of bone‑sawing? New laser cuts to record depths
Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have disc...
-
Southern Swedish company Aqilion develops drug for eosinophilic esophagitis
When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...
-
Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow
Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.
-
Investor Network Backs Early-Stage Nordic Innovation
Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested...
-
Novo Nordisk Foundation commits billions to Danish life science incubator
The Novo Nordisk Foundation grants up to DKK 5.5 billion to life science and deep‑tech incubator Bioinnovation Institute (BII) in Copenhagen.
-
Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”
With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Mak...
-
Genmab drops another ADC candidate from billion‑dollar ProfoundBio deal
Danish biotech Genmab has discontinued development of its antibody‑drug conjugate (ADC) candidate GEN1160, citing low patient enrollment in an early‑stage cancer trial.
-
Study: Autism as common in girls as in boys
Autism may be just as common in girls as in boys, but girls are diagnosed significantly later and less often during childhood, according to a large Swedish registry study.
-
Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”
The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a r...
-
Asgard teaches tumours to self‑destruct – moving closer to clinical trials
Swedish biotech Asgard Therapeutics not only has an evocative name, but also a remarkably exciting approach to cancer treatment: getting tumour cells to reprogr...
-
Novo Nordisk strengthens board after turbulent year
Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with ex...
-
Acne medication may be the solution when hair starts falling out
A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
BREAKING